Insider · CIK 0001438462
Frederick M. Hudson
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.), SCPH (scPharmaceuticals Inc.). First filing Nov 12, 2024, latest Mar 16, 2026.
Frederick M. Hudson files SEC Form 4 as director at SUPN (SUPERNUS PHARMACEUTICALS, INC.), and also at SCPH (scPharmaceuticals Inc.). Since Nov 12, 2024, Frederick M. Hudson has reported 0 open-market buys worth $0 and 3 open-market sells worth $903k, the latest filed on Mar 16, 2026.
A track record needs three past buys with six months of prices behind them; Frederick M. Hudson has 0, so none is measured yet.
The newest scored trade: sold $272k of SUPN on Mar 12, 2026, filed Mar 16, 2026, scored 43 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $272k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | SUPERNUS PHARMACEUTICALS, INC. | $272k 5,369 shares | -8% | +67% from low-11% from high | |
| 49Moderate | SUPERNUS PHARMACEUTICALS, INC. | $315k 7,457 shares | -14% | +41% from low-1% from high | |
| 49Moderate | SUPERNUS PHARMACEUTICALS, INC. | $316k 8,722 shares | -23% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 5,369 0.01% of outstanding | $272k | Mar 12, 2026 | none |
| Aug 14, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 7,457 0.01% of outstanding | $315k | Aug 14, 2025 | none |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 8,722 0.02% of outstanding | $316k | Nov 8, 2024 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -5,369 | $50.61 | $272k | 60,413 | Mar 16, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +4,475 | $0.00 | $0 | 65,782 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -4,475 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +2,989 | $0.00 | $0 | 2,989 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +4,977 | $0.00 | $0 | 4,977 | Feb 20, 2026 |
| Jan 9, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +15,000 | $12.98 | $195k | 61,307 | Jan 12, 2026 |
| Jan 9, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -19,750 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,300 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,124 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Aug 14, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -7,457 | $42.26 | $315k | 46,307 | Aug 18, 2025 |
| Jun 3, 2025 | SCPH scPharmaceuticals Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 5, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +5,369 | $0.00 | $0 | 53,764 | Feb 24, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitsderivative | -5,369 | $0.00 | $0 | 0 | Feb 24, 2025 |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +7,296 | $0.00 | $0 | 7,296 | Feb 21, 2025 |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +4,475 | $0.00 | $0 | 4,475 | Feb 21, 2025 |
| Jan 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +20,000 | $9.13 | $183k | 48,395 | Jan 23, 2025 |
| Jan 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Director Stock Option (Right to Buy)derivative | -20,000 | $0.00 | $0 | 0 | Jan 23, 2025 |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -8,722 | $36.28 | $316k | 28,395 | Nov 12, 2024 |
Questions about Frederick M. Hudson
Answered from the filings on this page, as of the latest one.
Is Frederick M. Hudson buying or selling?
In the last 12 months Frederick M. Hudson reported 0 open-market buys worth $0 and 1 open-market sell worth $272k on SEC Form 4; the latest was sold $272k of SUPN on Mar 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Frederick M. Hudson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Frederick M. Hudson has 0.
Where does Frederick M. Hudson file Form 4?
Frederick M. Hudson has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.); SCPH (scPharmaceuticals Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.